Which has stronger valuation and earnings, AVTX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalo Therapeutics $60K 17,644.27 -$78.26M -$4.37 N/A Telix Pharmaceuticals $803.79M 4.94 -$7.12M N/A N/A

Is AVTX or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Telix Pharmaceuticals N/A N/A N/A

Is AVTX or DNLI more profitable?

Denali Therapeutics' return on equity of -55.27% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Denali Therapeutics N/A -55.27% -44.24%

Is AVTX or VKTX more profitable?

Avalo Therapeutics' return on equity of -58.03% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Viking Therapeutics N/A -94.56% -82.75%

Avalo Therapeutics (AVTX) Competitors

$19.74 +0.47 (+2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$19.75 +0.01 (+0.05%)

As of 04:41 PM Eastern

Compare

AVTX vs. TLX, DNLI, VKTX, LEGN, and RCUS

Should you buy Avalo Therapeutics stock or one of its competitors? Avalo Therapeutics's main competitors and comparable companies include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Viking Therapeutics (VKTX), Legend Biotech (LEGN), and Arcus Biosciences (RCUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Avalo Therapeutics (NASDAQ:AVTX) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Avalo Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than Avalo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,644.27	-$78.26M	-$4.37	N/A
Telix Pharmaceuticals	$803.79M	4.94	-$7.12M	N/A	N/A

In the previous week, Telix Pharmaceuticals had 15 more articles in the media than Avalo Therapeutics. MarketBeat recorded 16 mentions for Telix Pharmaceuticals and 1 mentions for Avalo Therapeutics. Telix Pharmaceuticals' average media sentiment score of 0.34 beat Avalo Therapeutics' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Neutral
Telix Pharmaceuticals	Neutral

87.1% of Avalo Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Telix Pharmaceuticals' return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Telix Pharmaceuticals	N/A	N/A	N/A

Avalo Therapeutics presently has a consensus price target of $45.10, indicating a potential upside of 128.47%. Telix Pharmaceuticals has a consensus price target of $20.40, indicating a potential upside of 74.51%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Telix Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Avalo Therapeutics and Telix Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Avalo Therapeutics compare to Denali Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Avalo Therapeutics currently has a consensus target price of $45.10, indicating a potential upside of 128.47%. Denali Therapeutics has a consensus target price of $35.85, indicating a potential upside of 43.79%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Avalo Therapeutics is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Denali Therapeutics had 6 more articles in the media than Avalo Therapeutics. MarketBeat recorded 7 mentions for Denali Therapeutics and 1 mentions for Avalo Therapeutics. Denali Therapeutics' average media sentiment score of 1.26 beat Avalo Therapeutics' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Neutral
Denali Therapeutics	Positive

Avalo Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Avalo Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,644.27	-$78.26M	-$4.37	N/A
Denali Therapeutics	$330.53M	12.06	-$512.54M	-$2.84	N/A

Denali Therapeutics' return on equity of -55.27% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Denali Therapeutics	N/A	-55.27%	-44.24%

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Denali Therapeutics beats Avalo Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Avalo Therapeutics compare to Viking Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Avalo Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Avalo Therapeutics' return on equity of -58.03% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Viking Therapeutics	N/A	-94.56%	-82.75%

Avalo Therapeutics has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,644.27	-$78.26M	-$4.37	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

In the previous week, Viking Therapeutics had 6 more articles in the media than Avalo Therapeutics. MarketBeat recorded 7 mentions for Viking Therapeutics and 1 mentions for Avalo Therapeutics. Viking Therapeutics' average media sentiment score of 1.49 beat Avalo Therapeutics' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Neutral
Viking Therapeutics	Positive

Avalo Therapeutics currently has a consensus target price of $45.10, indicating a potential upside of 128.47%. Viking Therapeutics has a consensus target price of $96.63, indicating a potential upside of 182.78%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Avalo Therapeutics beats Viking Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Avalo Therapeutics compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Avalo Therapeutics (NASDAQ:AVTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Avalo Therapeutics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.85	-$296.80M	-$0.25	N/A
Avalo Therapeutics	$60K	17,644.27	-$78.26M	-$4.37	N/A

Legend Biotech has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -7.21%. Legend Biotech's return on equity of -8.71% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Legend Biotech presently has a consensus target price of $52.29, suggesting a potential upside of 145.47%. Avalo Therapeutics has a consensus target price of $45.10, suggesting a potential upside of 128.47%. Given Legend Biotech's higher probable upside, research analysts plainly believe Legend Biotech is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Legend Biotech had 5 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for Legend Biotech and 1 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.00 beat Legend Biotech's score of -0.12 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Legend Biotech	Neutral
Avalo Therapeutics	Neutral

Summary

Avalo Therapeutics beats Legend Biotech on 10 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Arcus Biosciences?

Avalo Therapeutics (NASDAQ:AVTX) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalo Therapeutics presently has a consensus target price of $45.10, indicating a potential upside of 128.47%. Arcus Biosciences has a consensus target price of $37.80, indicating a potential upside of 20.29%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Avalo Therapeutics is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Avalo Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -393.16%. Avalo Therapeutics' return on equity of -58.03% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

Avalo Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

In the previous week, Arcus Biosciences had 10 more articles in the media than Avalo Therapeutics. MarketBeat recorded 11 mentions for Arcus Biosciences and 1 mentions for Avalo Therapeutics. Arcus Biosciences' average media sentiment score of 0.84 beat Avalo Therapeutics' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Avalo Therapeutics	Neutral
Arcus Biosciences	Positive

Avalo Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,644.27	-$78.26M	-$4.37	N/A
Arcus Biosciences	$247M	16.20	-$353M	-$3.90	N/A

Summary

Avalo Therapeutics beats Arcus Biosciences on 8 of the 15 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTX vs. The Competition

Export

Metric	Avalo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.03B	$4.00B	$7.34B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-4.52	11.81	270.94	24.14
Price / Sales	17,644.27	1,381.21	634.79	96.73
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	2.36	16.86	13.14	6.25
Net Income	-$78.26M	-$22.76M	$3.46B	$347.86M
7 Day Performance	0.15%	4.71%	3.23%	1.57%
1 Month Performance	7.05%	12.26%	8.82%	5.24%
1 Year Performance	110.00%	60.84%	27.70%	17.87%

Avalo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTX Avalo Therapeutics	2.4295 of 5 stars	$19.74 +2.4%	$45.10 +128.5%	+95.0%	$1.03B	$60K	N/A	40
TLX Telix Pharmaceuticals	3.8452 of 5 stars	$11.88 +1.3%	$20.40 +71.7%	-6.4%	$4.02B	$803.79M	N/A	1,184
DNLI Denali Therapeutics	3.3706 of 5 stars	$24.31 -0.2%	$35.92 +47.7%	+56.2%	$3.90B	$330.53M	N/A	430	Positive News Analyst Forecast Gap Up
VKTX Viking Therapeutics	3.317 of 5 stars	$33.37 -0.8%	$96.63 +189.6%	+27.8%	$3.87B	N/A	N/A	20
LEGN Legend Biotech	3.1482 of 5 stars	$21.92 +6.2%	$52.29 +138.5%	-41.1%	$3.78B	$1.03B	N/A	2,965

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTX) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avalo Therapeutics (AVTX) Competitors

AVTX vs. TLX, DNLI, VKTX, LEGN, and RCUS

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Summary

How does Avalo Therapeutics compare to Viking Therapeutics?

Summary

How does Avalo Therapeutics compare to Legend Biotech?

Summary

How does Avalo Therapeutics compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avalo Therapeutics (AVTX) Competitors

AVTX vs. TLX, DNLI, VKTX, LEGN, and RCUS

How does Avalo Therapeutics compare to Telix Pharmaceuticals?

Which has more risk and volatility, AVTX or TLX?

Which has stronger valuation and earnings, AVTX or TLX?

Does the media favor AVTX or TLX?

Do institutionals and insiders have more ownership in AVTX or TLX?

Is AVTX or TLX more profitable?

Do analysts recommend AVTX or TLX?

Summary

How does Avalo Therapeutics compare to Denali Therapeutics?

Do analysts recommend AVTX or DNLI?

Does the media favor AVTX or DNLI?

Which has more volatility and risk, AVTX or DNLI?

Which has better earnings & valuation, AVTX or DNLI?

Is AVTX or DNLI more profitable?

Do insiders and institutionals have more ownership in AVTX or DNLI?

Summary

How does Avalo Therapeutics compare to Viking Therapeutics?

Which has more volatility & risk, AVTX or VKTX?

Do institutionals and insiders believe in AVTX or VKTX?

Is AVTX or VKTX more profitable?

Which has stronger earnings & valuation, AVTX or VKTX?

Does the media prefer AVTX or VKTX?

Do analysts prefer AVTX or VKTX?

Summary

How does Avalo Therapeutics compare to Legend Biotech?

Do insiders and institutionals hold more shares of LEGN or AVTX?

Which has stronger earnings and valuation, LEGN or AVTX?

Which has more risk and volatility, LEGN or AVTX?

Is LEGN or AVTX more profitable?

Do analysts prefer LEGN or AVTX?

Does the media favor LEGN or AVTX?

Summary

How does Avalo Therapeutics compare to Arcus Biosciences?

Do insiders and institutionals have more ownership in AVTX or RCUS?

Do analysts rate AVTX or RCUS?

Is AVTX or RCUS more profitable?

Which has more volatility & risk, AVTX or RCUS?

Does the media prefer AVTX or RCUS?

Which has better valuation and earnings, AVTX or RCUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX vs. The Competition

Avalo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools